Experienced Team Our Vitamin B12 Boost administered by our experienced team is the boost you need
Because AOD 9604 focuses on lipolysis (fat burning) rather than just rapid weight loss through calorie restriction, it is often touted as a way to help maintain muscle while losing fat
Type 2 Diabetes With Obesity CagriSema REDEFINE 2 showed 13.7% weight loss with 73.5% of T2D patients achieving HbA1c of 6.5% or less, exceeding semaglutide's glycemic and weight results in T2D trials
Follow the storage instructions on the vial and pharmacy label
Full disclaimer 1.AOD-9604 is a 16-amino acid peptide fragment derived from human growth hormone (hGH residues 177-191) with added tyrosine, developed by Metabolic Pharmaceuticals for obesity treatment 2.Proposed mechanism: selective stimulation of lipolysis (fat breakdown) and inhibition of lipogenesis (fat formation) without growth hormone-like effects on IGF-1 or blood glucose 3.Failed Phase 2b clinical trial for obesity (2007)did not demonstrate statistically significant weight loss versus placebo, terminating clinical development for this indication 4.Received FDA "Generally Recognized as Safe" (GRAS) designation in 2023 as a food substance, but this is NOT a drug approval and does not establish efficacy for weight loss 5.Regulatory status: not FDA-approved as a drug, prohibited by WADA, and insufficient evidence for weight loss efficacy
Moreover, the Eb-domain also contains two predicted molecular recognition features (MoRFs) and two phosphorylation sites